Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2005-06-01
2008-11-04
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
C549S293000
Reexamination Certificate
active
07446196
ABSTRACT:
Leptomycin-type compounds according to Formula Iwherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.
REFERENCES:
patent: 4725621 (1988-02-01), Bunge
patent: 4771070 (1988-09-01), Hokanson
patent: 4792522 (1988-12-01), Nettleton
patent: 5510118 (1996-04-01), Bosch
patent: 5534270 (1996-07-01), De Castro
patent: 5662883 (1997-09-01), Bagchi
patent: 2003/0162740 (2003-08-01), Wang
patent: WO 81/01145 (1981-04-01), None
patent: WO 2004/000212 (2005-01-01), None
Kudo et al. Experimental Cell Research, 1998, 242(2), 54-546.
Kuhnt et al. Applied Environmental Microbiology 1998, 64(2), 714-720.
U.S. Appl. No. 10/856,703, filed May 27, 2004, Johnson, Jr.
Carl et al.,J. Med. Chem. 1981, 24 (3), 479-480, “A Novel Connector Linkage Applicable in Prodrug Design”.
Chemical Abstracts No. 105:102629 (abstract of JP 61-109717 A2 (1986)).
Doherty et al.,J. Nat. Cancer Inst. 2003, 95(24), 1859-1868, “Cell Cycle Checkpoint Function in Bladder Cancer”.
Fukuda et al.,Nature1997, 390, 308-311, “CRM1 is responsible for intracellular transport mediated by the nuclear export signal”.
Hamamoto et al.,J. Antibiotics1983, 36 (6), 639-645, “Leptomycins A and B, New Antifungal Antibiotics I. Taxonomy of the Producing Strain and Their Fermentation, Purification and Characterization”.
Hayakawa et al.,J. Antibiotics1987, 40 (9), 1349-1352, “New Antitumor Antibiotics, Anguinomycins A and B”.
Inoue et al.,J. Biol. Chem. 2002, 277 (17), 15053-15060, “Nuclear Import and Export Signals in Control of the p53-related Protein p73”.
Kobayashi et al., Ensho, Saisei 2004, 24(5), 578-583, “Role of matrix metalloproteinase-9 expression on cutaneous inflammation: possible treatment by leptomycin B application” (abstract).
Komiyama et al.,J. Antibiotics1985, 38 (2), 220-223, “Structural Study of a New Antitumor Antibiotic, Kazusamycin”.
Komiyama et al.,J. Antibiotics1985, 38 (2), 224-229, “Antitumor Activity of a New Antibiotic, Kazusamycin”.
Komiyama et al.,J. Antibiotics1985, 38 (3), 427-429, “Antitumor activity of leptomycin B”.
Kudo et al.,Exp. Cell Res. 1998, 242, 540-547, “Lepto-mycin B Inhibition of Signal Mediated Nuclear Export by Direct Binding to CRM1”.
Kudo et al.,Proc. Nat'l Acad. Sci. (USA) 1999, 96 (3), 9112-9117, “Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region”.
Kuhnt et al.,Applied Environ. Microbiol. 1998, 64 (2), 714-720, “Microbial Conversion Products of Leptomycin B”.
Lane et al.,Proc. Nat'l Acad. Sci. (USA) 2000, 97, 8501-8506, “Activation of p53 in cervical carcinoma cells by small molecules”.
Marabese et al.,Nucleic Acids Res. 2003 31 (22), 6624-6632, “DNA damage induces transcriptional activation of p73 by removing C-EBPa repression on E2F1”.
Meissner et al., FEBS Letters 2004, 576(1-2), 27-30, “Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms” (abstract).
Nishi et al.,J. Biol. Chem. 1994, 269 (9), 6320-6324, “Leptomycin B Targets a Regulatory Cascade of crm1, a Fission Yeast Nuclear Protein, Involved in Control of Higher Order Chromosome Structure and Gene Expression”.
Peehl et al.,Prostate2003, 54, 258-267, “Leptomycin B Stabilizes and Activates p53 in Primary Prostatic Epithelial Cells and Induces Apoptosis in the LNCaP Cell Line”.
University of Dundee, Dept. Surgery & Molecular Oncology, Lain Group Website, http://www.dundee.ac.uk/surgery/Non-Genotoxic.htm, accessed Dec. 6, 2004, “Non-genotoxic activation of the p53 tumor suppressor function”.
Vigneri et al.,Nature Medicine2001, 7, 228-234, “Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase”.
Vousden et al.,Nat. Rev. Cancer2002, 2, 594-504, “Live or Let Die: the Cell's Response to p53”.
Yokomizo et al.,Oncogene1999 18(8), 1629-1633, “Overexpression of the wild type p73 gene in human bladder cancer” (abstract).
Dong Steven
Hearn Brian
Myles David C.
Santi Daniel V.
Ashley Gary
Chandrakumar Nizal S
Korsen Elliott
Kosan Biosciences Incorporated
Seaman D. Margaret
LandOfFree
Leptomycin compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Leptomycin compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Leptomycin compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4020253